| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02903524 | Breast Cancer | Drug: Doxorubicin Hydrochloride Liposome injection and cyclophosphamide|Drug: pirarubicin and cyclophosphamide | Hebei Medical University Fourth Hospital | Phase 4 | 2016-09-01 | 2016-09-15 |
| NCT03030157 | Intravesical Instillation | Drug: pirarubicin(THP) | RenJi Hospital|Shanghai Pudong Hospital|Shanghai Pudong New Area Gongli Hospital | Phase 2 | 2017-01-01 | 2017-01-20 |
| NCT01249690 | Multiple Myeloma | Drug: Bortezomib,Pirarubicin,Dexamethasone|Drug: Thalidomide,Pirarubicin,Dexamethasone | Second Military Medical University|Zhejiang University|Peking University People's Hospital|Fourth Military Medical University|Xiangya Hospital of Central South University|Institute of Hematology & Blood Diseases Hospital|Union hospital of Fujian Medical University|Harbin Institute of Hematology and Oncology|First Affiliated Hospital, Sun Yat-Sen University|Beijing Jishuitan Hospital | Phase 4 | 2010-06-01 | 2010-11-29 |
| NCT02740426 | Upper Tract Urothelial Carcinoma|Bladder Recurrence | Drug: Pirarubicin | Peking University First Hospital | Phase 2 | 2016-08-01 | 2016-08-24 |
| NCT02923557 | Bladder Recurrence|Upper Tract Urothelial Carcinoma|Nephroureterectomy | Drug: Pirarubicin | Peking University First Hospital | Phase 2 | 2016-11-01 | 2016-11-15 |
| NCT02613026 | Breast Neoplasms | Drug: Pirarubicin|Drug: Docetaxel|Drug: Cyclophosphamide | 307 Hospital of PLA | Phase 3 | 2009-07-01 | 2015-11-22 |
| NCT02547350 | Upper Tract Urothelial Carcinoma|Bladder Recurrence | Drug: pharmorubicin or pirarubicin | Xuesong Li|Peking University First Hospital | Phase 2 | 2015-09-01 | 2015-09-09 |
| NCT01746992 | ALK-negative Anaplastic Large Cell Lymphoma|Peripherial T Cell Lymphoma,Not Otherwise Specified|Angioimmunoblastic T Cell Lymphoma|Enteropathy Associated T Cell Lymphoma|Hepatosplenic T Cell Lymphoma|Subcutaneous Panniculitis Like T Cell Lymphoma | Drug: Cyclophosphamide 750mg/m2|Drug: Vincristine 1.4mg/m2|Drug: Doxorubicin 50mg/m2|Drug: prednisone 60mg/m2|Drug: ifosfamide 2000mg/m2|Drug: pirarubicin 50mg/m2|Drug: pirarubicin 25mg/m2|Drug: Etoposide phosphate 100mg/m2|Drug: methotrexate 1500mg/m2 | Ruijin Hospital | Phase 4 | 2012-09-01 | 2013-11-24 |
| NCT02585479 | Hepatocellular Carcinoma | Drug: Pirarubicin|Drug: Oxaliplatin|Drug: Lipiodol|Device: Gelfoam | Guangxi Medical University | Phase 2|Phase 3 | 2015-10-01 | 2015-10-22 |
| NCT02584556 | Hepatocellular Carcinoma | Drug: systemic chemotherapy|Drug: Transcatheter Arterial Chemoembolization | Guangxi Medical University | Phase 2|Phase 3 | 2015-10-01 | 2015-10-21 |
| NCT02755311 | Hepatocellular Carcinoma | Procedure: liver resection|Procedure: transarterial chemoembolization|Drug: carboplatin|Drug: lipiodol|Drug: epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil|Other: absorbable gelatin sponge particles | Sun Yat-sen University | Phase 3 | 2014-03-01 | 2016-04-27 |
| NCT02838225 | Breast Cancer | Drug: Docetaxel, Doxorubicin|Drug: Docetaxel, Doxorubicin, Cyclophosphamide | Peking Union Medical College Hospital | Phase 2 | 2009-01-01 | 2016-07-17 |
| NCT02301091 | Hepatocellular Carcinoma | Procedure: TACE|Procedure: RFA|Drug: pirarubicin,mitomycin and lobaplatin | Ming Zhao|Sun Yat-sen University | Phase 3 | 2014-10-01 | 2016-04-13 |
| NCT02724358 | Hepatocellular Carcinoma|TACE|Notch1|Rg3 | Procedure: TACE|Drug: Rg3|Other: TACE + Rg3|Procedure: protective therapy | Eastern Hepatobiliary Surgery Hospital | | 2012-12-01 | 2016-03-28 |
| NCT01430013 | T Cell Lymphoma | Drug: Endostar and CHOPT | Tianjin Medical University Cancer Institute and Hospital|Simcere Pharmaceutical Co., Ltd | Phase 2 | 2011-06-01 | 2015-11-02 |
| NCT02396043 | Lymphoma, Lymphoblastic | Drug: induction|Drug: induction|Drug: protocol M|Drug: maintenance therapy|Drug: reinduction|Drug: reinduction|Drug: Intrathecal (IT) | Sun Yat-sen University | Phase 2 | 2015-03-01 | 2016-10-18 |
| NCT02525952 | Hepatocellular Carcinoma | Procedure: Hepatectomy|Procedure: TACE | Eastern Hepatobiliary Surgery Hospital | | 2015-10-01 | 2016-03-30 |
| NCT02435953 | Hepatocellular Carcinoma|Chemoembolization, Therapeutic|Ablation Techniques, RFA | Procedure: TACE|Procedure: RFA | Ming Zhao|Sun Yat-sen University | Phase 4 | 2015-04-01 | 2016-10-12 |
| NCT02956772 | Primary Hepatocellular Carcinoma | Drug: TACE|Drug: Arsenic trioxide | Hunan Provincial People's Hospital | Phase 2 | 2016-11-01 | 2017-02-21 |
| NCT00131053 | Lymphoblastic Leukemia, Acute | Drug: Methotrexate|Drug: Prednisolone|Drug: Dexamethasone|Drug: Vincristine|Drug: Pirarubicin|Drug: Cyclophosphamide|Drug: L-asparaginase|Drug: Cytarabine|Drug: Hydrocortisone|Drug: Mercaptopurine | Japan Adult Leukemia Study Group | Phase 2 | 2002-09-01 | 2008-11-13 |
